Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia

被引:93
作者
Yamada, Y
Hatta, Y
Murata, K
Sugawara, K
Ikeda, S
Mine, M
Maeda, T
Hirakata, Y
Kamihira, S
Tsukasaki, K
Ogawa, S
Hirai, H
Koeffler, HP
Tomonaga, M
机构
[1] NAGASAKI UNIV,SCH MED,DEPT HEMATOL,NAGASAKI 852,JAPAN
[2] NAGASAKI UNIV,SCH MED,SCI DATA CTR ATOM BOMB DISASTER,NAGASAKI 852,JAPAN
[3] UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN
[4] UNIV CALIF LOS ANGELES,SCH MED,CEDARS SINAI RES INST,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024
[5] SASEBO GEN HOSP,DEPT HEMATOL,SASEBO,JAPAN
关键词
D O I
10.1200/JCO.1997.15.5.1778
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the frequency of the deletions of p15/p16 genes in adult T-cell leukemia (ATL) cells and to evaluate their value in the diagnosis of clinical subtypes of ATL patients and the prediction of their clinical outcome. Materials and Methods: Peripheral-blood samples from 114 patients with ATL were examined by Southern blot analysis, In five chronic-type patients who showed disease progression to acute type, serial samples also were examined, Results: Among 114 patients, 28 (24.6%) showed the deletions of p15 and/or p16 genes, The results were well correlated with the clinical subtypes, Patients with deleted p15 and/or p16 genes had significantly shorter survival times than the patients in whom both genes were preserved (P < .0001), A similar decline in survival time was observed in the analyses within the same subtypes. In multivariate analysis using the Cox proportional hazard model, the deletions of p15 and/or p16 genes emerged as an independent prognostic indicator. Moreover, three of the five chronic-type patients who progressed to acute type lost the p16 gene alone or both the p15 and p16 genes at their exacerbation phase. Conclusion: The results suggest the following: (1) that the deletions of p15 and/or p16 genes play a key role in the progression of ATL; and (2) that these deletions are reliable prognostic factors that predict shortened survival times. (C) 1997 by American Society of Clinical Oncology.
引用
收藏
页码:1778 / 1785
页数:8
相关论文
共 46 条
[1]   FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA [J].
CALDAS, C ;
HAHN, SA ;
DACOSTA, LT ;
REDSTON, MS ;
SCHUTTE, M ;
SEYMOUR, AB ;
WEINSTEIN, CL ;
HRUBAN, RH ;
YEO, CJ ;
KERN, SE .
NATURE GENETICS, 1994, 8 (01) :27-32
[2]   THE CELL-CYCLE AND THE RETINOBLASTOMA PROTEIN FAMILY [J].
EWEN, ME .
CANCER AND METASTASIS REVIEWS, 1994, 13 (01) :45-66
[3]   DETECTION OF HOMOZYGOUS DELETIONS OF THE CYCLIN-DEPENDENT KINASE-4 INHIBITOR (P16) GENE IN ACUTE LYMPHOBLASTIC-LEUKEMIA AND ASSOCIATION WITH ADVERSE PROGNOSTIC FEATURES [J].
FIZZOTTI, M ;
CIMINO, G ;
PISEGNA, S ;
ALIMENA, G ;
QUARTARONE, C ;
MANDELLI, F ;
PELICCI, PG ;
LOCOCO, F .
BLOOD, 1995, 85 (10) :2685-2690
[4]  
GERDES J, 1984, J IMMUNOL, V133, P1710
[5]  
GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531
[6]   Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16(INK4A)/CDKN2, MTS2/p15(INK4B), p53, and Rb genes in primary lymphoid malignancies [J].
Hangaishi, A ;
Ogawa, S ;
Imamura, N ;
Miyawaki, S ;
Miura, Y ;
Uike, N ;
Shimazaki, C ;
Emi, N ;
Takeyama, K ;
Hirosawa, S ;
Kamada, N ;
Kobayashi, Y ;
Takemoto, Y ;
Kitani, T ;
Toyama, K ;
Ohtake, S ;
Yazaki, Y ;
Ueda, R ;
Hirai, H .
BLOOD, 1996, 87 (12) :4949-4958
[7]   P15(INK4B) IS A POTENTIAL EFFECTOR OF TGF-BETA-INDUCED CELL-CYCLE ARREST [J].
HANNON, GJ ;
BEACH, D .
NATURE, 1994, 371 (6494) :257-261
[8]   HOMOZYGOUS DELETIONS OF THE P15 (MTS2) AND P16 (CDKN2/MTS1) GENES IN ADULT T-CELL LEUKEMIA [J].
HATTA, Y ;
HIRAMA, T ;
MILLER, CW ;
YAMADA, Y ;
TOMONAGA, M ;
KOEFFLER, HP .
BLOOD, 1995, 85 (10) :2699-2704
[9]   SOMATIC MUTATIONS OF THE MTS (MULTIPLE TUMOR-SUPPRESSOR)-1 CDK41 (CYCLIN-DEPENDENT KINASE-4 INHIBITOR) GENE IN HUMAN PRIMARY NONSMALL CELL LUNG CARCINOMAS [J].
HAYASHI, N ;
SUGIMOTO, Y ;
TSUCHIYA, E ;
OGAWA, M ;
NAKAMURA, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 202 (03) :1426-1430
[10]  
Herman JG, 1996, CANCER RES, V56, P722